<DOC>
	<DOCNO>NCT00599274</DOCNO>
	<brief_summary>The purpose study find weekly Avonex work well three time week Rebif subject relapse multiple sclerosis .</brief_summary>
	<brief_title>Study Determine Avonex Rebif Work Comparably Well Subjects With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>This Phase 4 , multicenter , prospective retrospective , long-term observational study Avonex速 Rebif速 determine efficacy , tolerability , safety subject relapse MS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Must receive AVONEX速 Rebif速 . Must confirm diagnosis relapsingremitting MS use Poser criterion . Must experience least 2 relapse within 3 year period prior initiation treatment . Must EDSS score 0.0 5.5 , inclusive . History severe allergic anaphylactic reaction hypersensitivity human albumin , interferon , component drug formulation . History poorly control hypertension and/or clinically significant major disease . History uncontrolled seizure within 3 month prior enrollment . History suicidal ideation episode severe depression within 3 month prior enrollment . Serious local infection systemic infection within 8 week prior enrollment . Treatment certain agent treat MS symptom underlie disease . Treatment investigational product Previous participation study . Other Protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Interferon beta 1a</keyword>
	<keyword>Avonex</keyword>
</DOC>